<p>Hepatic Impairment:<br />
Intravenous:&nbsp;</p>

<ul>
	<li><strong>Cervical cancer</strong>:&nbsp;Dose adjustments may be needed.</li>
	<li><strong>Breast cancer</strong>, Ovarian<strong>&nbsp;cancer</strong>:&nbsp;Dose adjustments may be needed.</li>
	<li><strong>Non-small cell lung cancer</strong>:&nbsp;Massive liver metastases(&gt;75% of liver volume replaced by the tumour): Decrease dose by&nbsp;1/3. Bilirubin 2.1-3 mg/100 ml: Reduce IV dose by 50%. Bilirubin &gt;3 mg/100 ml: Reduce IV dose by 75%.</li>
</ul>

<p>Oral:&nbsp;</p>

<ul>
	<li><strong>Massive liver metastases(&gt;75% of liver volume replaced by&nbsp;</strong>the tumour<strong>)</strong>: Decrease dose by&nbsp;1/3. Bilirubin 2.1-3 mg/100 ml: Reduce IV dose by 50%. Bilirubin &gt;3 mg/100 ml: Reduce IV dose by 75%.</li>
</ul>